表紙
市場調查報告書

疼痛管理用非鴉片類藥物的出現

Emerging Non-opiod Pharmaceuticals for Pain Management

出版商 Frost & Sullivan 商品編碼 940881
出版日期 內容資訊 英文 51 Pages
商品交期: 最快1-2個工作天內
價格
疼痛管理用非鴉片類藥物的出現 Emerging Non-opiod Pharmaceuticals for Pain Management
出版日期: 2020年05月27日內容資訊: 英文 51 Pages
簡介

本調查主要領域為神經障礙性疼痛、術後疼痛、癌性疼痛、慢性疼痛與偏頭痛。

本報告針對疼痛管理用非鴉片類藥物市場調查、提供技術進步與市場動向、新興技術及創新企業、成長機會與專利情況分析。

第1章 摘要整理

  • 主要調查結果
  • 分析框架:Frost&Sullivan計分鏈
  • 調查方法

第2章 技術情勢、動向

  • 全球非鴉片類市場
  • NSAID對持續疼痛治療很重要
  • 非鴉片類藥物種類
  • 疼痛管理用開發的非鴉片類分類
  • 最近被承認地疼痛管理用單株抗體
  • 最新非鴉片類鎮痛藥
  • 疼痛治療的高度學術研究

第3章 創新雷達

  • 新興技術創新雷達
  • 計分方式概要
  • QBioMed
  • Centrexion Therapeutics
  • Concentric Analgesics
  • Xenon Pharmaceuticals
  • KinetaBio
  • Navega Therapeutics
  • Tetra Biopharma
  • Vapogenix

第4章 成長機會

  • 疼痛治療的創新藍圖
  • 成長機會1:R&D投資
  • 成長機會2:技術融合
  • 結論

第5章 專利分析

  • 非鴉片類藥物的IP概要
  • 主要藥物專利保持者
  • 專利情況

6.0附錄

目錄
Product Code: D97A

Emerging narcotic-free therapies

The research provides technological advances and insights across non-opioid pharmaceuticals for the management of pain. Key application areas explored in the research include neuropathic pain, migrane, post-surgical pain, cancer pain, chronic pain and migraine. The research encompasses technological advances across Nav1.7 inhibitors, Calcitonin Gene-related peptide inhibitors, Platelet rich plasma therapy, Ditans, Hydrogel therapy, and stem cell therapy among several others.

The research also provides competitive intelligence across emerging innovators in this space, while provide insights across the patent landscape for non-narcotic pain therapy.

Table of Contents

1.0 Executive Summary

  • 1.1. Key Findings
  • 1.2. Analysis Framework: Frost & Sullivan's Core Value
  • 1.3. Research Methodology

2.0 Technology Landscape and Trends

  • 2.1. Global Non-opioid Market
  • 2.2. NSAIDs Continue to be Important for Pain Treatment
  • 2.3. Types of Non-opioid Pharmaceuticals
  • 2.4. Categories of Non-opioids in Development for Pain Management
  • 2.4.1. Recently Approved Monoclonal Antibodies for Pain Management
  • 2.5. Emerging Non-opioid Analgesics
  • 2.6. Advanced Academic Researches in Pain Therapy
  • 2.6. Advanced Academic Researches in Pain Therapy (continued)

3.0 Innovation Radar

  • 3.1. Innovation Radar of Emerging Technologies
  • 3.2. Summary of the Scoring Methodology
  • 3.2.1. QBioMed
  • 3.2.1. QBioMed (continued)
  • 3.2.2. Centrexion Therapeutics
  • 3.2.2. Centrexion Therapeutics (continued)
  • 3.2.3. Concentric Analgesics
  • 3.2.3. Concentric Analgesics (continued)
  • 3.2.4. Xenon Pharmaceuticals
  • 3.2.4. Xenon Pharmaceuticals (continued)
  • 3.2.5. KinetaBio
  • 3.2.5. KinetaBio (continued)
  • 3.2.6. Navega Therapeutics
  • 3.2.6. Navega Therapeutics (continued)
  • 3.2.7. Tetra Biopharma
  • 3.2.7. Tetra Biopharma (continued)
  • 3.2.8. Vapogenix
  • 3.2.8. Vapogenix (continued)

4.0 Growth Opportunities

  • 4.1. Pain Therapy Innovations Roadmap
  • 4.2. Growth Opportunity 1: R&D Investment
  • 4.3. Growth Opportunity 2: Technology Convergence
  • 4.4. Conclusion

5.0 Patent Analysis

  • 5.1. IP Overview in Non-opioid Pharmaceuticals
  • 5.2. Leading Pharmaceutical Patent Holders
  • 5.3. Patent Scenario
  • 5.3Patent Scenario

6.0 Appendix

  • 6.1. List of Non-opioids in the Market
  • 6.2. Key Industry Contacts
  • 6.2. Key Industry Contacts (continued)
  • Legal Disclaimer